Moderna is a U.S.-based biotechnology company focused on the discovery, development, and manufacturing of messenger RNA (mRNA) therapeutics and vaccines. Headquartered in Cambridge, Massachusetts and founded in 2010, the company applies nucleic acid and delivery chemistry—particularly lipid nanoparticle (LNP) formulations—to encode proteins that can prevent or treat disease.
Moderna’s portfolio spans infectious diseases, oncology, rare diseases, cardiovascular and autoimmune disorders, supported by an integrated mRNA platform, in-house and partnered R&D, and clinical development programs. The company operates clinical and commercial manufacturing capabilities for mRNA drug substance and finished vaccines, including process development, scale-up, and quality systems. Moderna is publicly listed on Nasdaq under the ticker MRNA and is known for its COVID-19 vaccine (Spikevax), alongside a broader pipeline of investigational mRNA products.
